Washington Examiner: CMS names 10 drugs under new price controls, but advocates warn of 'cruel' side effects

The Centers for Medicare and Medicaid Services released on Tuesday the list of 10 medications that will be part of the price-setting Drug Price Negotiation Program through the Inflation Reduction Act, affecting an estimated 8.2 million patients with a range of illnesses, including heart failure, blood clots, diabetes, and arthritis.

Read More…

Previous
Previous

Blog Post: Biden’s Drug List Moves America’s Patient Doomsday Clock Closer to Midnight 

Next
Next

SFS Statement on the First Medicare Drugs to be “Negotiated”